Imagene AI
Category: AI in Healthcare
Imagene AI develops a pioneering precision oncology platform that uses artificial intelligence and multi-modal foundation models to analyze digital pathology images, providing rapid molecular and genomic insights to guide cancer treatment and drug development. Imagene AI was founded in 2020. The company is led by Dean Bitan. Based in Miami, Florida, United States (primary); Tel Aviv, Israel (secondary). Team size: 11-50. Total funding raised: $45 million. Latest round: Series B. Key investors include Larry Ellison, Blumberg Capital, Oracle, Eyal Gura, David Agus, PlayBeyondBio.
- Founded
- 2020
- Headquarters
- Miami, Florida, United States (primary); Tel Aviv, Israel (secondary)
- Team size
- 11-50
- Total funding
- $45 million
Value proposition
To reduce time-to-treatment from weeks to minutes by providing immediate, actionable genomic insights from standard pathology images, enabling faster clinical decisions and democratizing access to precision oncology.
Products and solutions
OI (Oncology Intelligence) Suite: An end-to-end platform for biomarker discovery and patient identification., CanvOI: A foundational AI model for oncology intelligence, developed in partnership with Oracle.
Unique value
The core innovation is a multi-modal AI foundation model that analyzes digitized pathology slides to predict a wide range of cancer biomarkers and genomic alterations without requiring physical tissue consumption or wet-lab processing for initial screening.
Target customer
Cancer centers, hospitals, pathology labs, and pharmaceutical companies engaged in oncology research and clinical trials.
Industries served
Healthcare (Oncology & Pathology), Pharmaceuticals & Biotechnology (R&D), Diagnostics Laboratories
Technology advantage
The platform's key advantages are its rapid turnaround time (minutes vs. weeks for traditional sequencing), cost-effectiveness, and scalability through a cloud-based model that integrates with existing digital pathology workflows.
How they differentiate
Imagene's primary differentiation is its ability to infer genomic biomarkers directly from standard H&E-stained pathology images in minutes, eliminating the need for slower, more expensive molecular testing as a first-line screening tool. It focuses on bridging histopathology and genomics.
Main competitors
PathAI, Paige.AI, Owkin, Ibex Medical Analytics, PreciseDx
Key partnerships
Oracle (for cloud infrastructure and co-development), AstraZeneca (strategic collaboration), Tempus (to bring rapid predictive assays to clinicians), Daiichi Sankyo (multimodal biomarker discovery collaboration, April 2026), Sheba Medical Center (precision oncology intelligence alliance), Shaare Zedek Medical Center (strategic data-AI collaboration), Tel Aviv Sourasky University Medical Center / Ichilov (clinical AI infrastructure for precision oncology and biopharma R&D, July 16, 2026), Proscia (Proscia Ready alliance and Concentriq integration for AI-powered IHC companion diagnostic development, August 18, 2026), CellCarta (expanded biomarker and companion diagnostic development collaboration, October 1, 2026)
Notable customers
AstraZeneca, Tempus, Daiichi Sankyo, Sheba Medical Center, Shaare Zedek Medical Center, Top-tier medical centers and pharmaceutical companies (specific names often under NDA).
Major milestones
Successfully raised $45 million in total funding., Received FDA Breakthrough Device Designation for an AI-based tool., Established key strategic partnerships with Oracle, Tempus, Daiichi Sankyo, Sheba Medical Center, and Shaare Zedek Medical Center., Launched OI Suite Discovery Program for biopharma researchers., Published multiple peer-reviewed studies validating the technology's performance., CanvOI foundation model trained on over 1.5 million biopsy images across 40+ organs.
Growth metrics
Expansion of strategic collaborations with major pharmaceutical and diagnostic companies including Daiichi Sankyo; launch of OI Suite Discovery Program providing complimentary access for biopharma researchers; CanvOI foundation model trained on over 1.5 million biopsy images across 40+ organs; new leadership hires including SVP Business Development, Head of Translational & Clinical Strategy, and VP of Product Marketing.
Market positioning
Positioned as a disruptive force in rapid cancer diagnostics, complementing traditional pathology and next-generation sequencing (NGS) by providing immediate, actionable insights for oncologists and pharmaceutical researchers.
Geographic focus
Global, with a strong presence in North America, Europe, and Israel.
Patents and IP
The company holds proprietary technology and algorithms related to its image-based biomarker detection, though specific patent numbers are not publicly detailed.
About Dean Bitan
Dean Bitan has extensive experience in business, technology, and product development. He began his career in 2010 as a Product Manager for the Israel Defense Forces, progressing to leadership roles including Project Manager and Head of Department. He co-founded startups such as Ping and Appload Software Solutions Ltd., and held key technical and management roles in several companies before becoming CEO at Imagene AI in 2020. He is also an Official Member and Contributor of the Forbes Business Council.
Latest news about Imagene AI
More AI in Healthcare companies
Official website: https://imagene-ai.com/